

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

12-15842-01

Docket or Reference number

Amendment No. 15

Delnor Hospital
975 North Fifth Avenue
St. Charles, IL 60174

In accordance with application dated January 31, 1984, License Number 12-15842-01 is amended as follows:

Items 6., 7., 8., and 9. are amended to add:

6. Byproduct, source,
and/or special nuclear
material

7. Chemical and/or
physical form

8. Maximum amount that
licensee may possess
at any one time
under this license

F. Any byproduct material
listed in Group VI of
Schedule A, Section
35.100 of 10 CFR 35

F. Any sealed source
listed in Group VI of
Schedule A, Section
35.100 of 10 CFR 35

F. 2000 millicuries
total for all
sources authorized
in Subitem 6.F

9. Authorized Use

F. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

Conditions 12. and 17. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Alvin A. Zeman, M.D.

Groups I, II, III and IV
Iodine-131 as iodide for treatment
of thyroid carcinoma
Xenon-133

James C. Pritchard, M.D.

Groups I, II and III
Xenon-133

Robert A. Carrara, M.D.

Groups I, II and III
Xenon-133

8506190052 850604
REG3 LIC30
12-15842-01
PDR

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

12-15842-01

Docket or Reference number

Amendment No. 15

Phillip E. Rathbun, M.D.

Groups I, II and III

Iodine-131 as iodide for treatment
of hyperthyroidism and cardiac
dysfunctionPhosphorus-32 as soluble phosphate
for treatment of polycythemia
vera, leukemia and bone metastases

Xenon-133

Nicholas C. Burriesci, M.D.

Groups I, II, III and IV

Iodine-131 as iodide for treatment
of thyroid carcinoma

Xenon-133

James G. Gagnon, M.D.

Group VI

Geoffrey L. Smoron, M.D.

Group VI

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated December 11, 1978, July 22, 1980, and January 31, 1984; letters dated January 31, 1979, June 5, 1980, October 27, 1980, October 13, 1981, March 9, 1982; and Model ALARA Program as contained in Appendix O of Regulatory Guide 10.8, dated October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

MAR 01 1984

Date

By

Ralph Meyer

Materials Licensing Section, Region III